Develops drugs for autoimmune diseases and pulmonary hypertension.
Jun 2026Revenue $7.53M/yrExpenses $604M/yr
No trendCash runway ≈ 4.7 years from Jun 2026
Figures by year
When will Roivant Sciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $7.53M and expenses $604M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Mar 2026 | $8.26M | $523M | −$515M |
| Mar 2025 | $29.1M | $1.03B | −$1.00B |
| Mar 2024 | $32.7M | −$4.46B | $4.50B |
| Mar 2023 | $31.5M | $938M | −$907M |
| Mar 2022 | $55.3M | $1.41B | −$1.35B |
| Mar 2021 | $23.8M | $1.09B | −$1.07B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.